Go with your Gut: Big Pharma and the Microbiome

Add this event to your calendar:
25/10/2016 16:00 25/10/2016 18:30 America/New_York Go with your Gut: Big Pharma and the Microbiome JLABS @ LabCentral , 700 Main St , Cambridge , MA 02139 Johnson & Johnson Innovation, JLABS false DD/MM/YYYY

Go with your Gut: Big Pharma and the Microbiome

JLABS @ LabCentral , 700 Main St , Cambridge , MA 02139

October 25, 2016 from 16:00 PM to 18:30 PM (EST)

$10 - $35

Have you heard the headlines? As AOBiome purports, "Bacteria is the new black". Or, as Ron Leuty puts it, "Big Pharma is hungry for bacteria".

Everyone is talking about the gut, and big pharma is intrigued. Johnson & Johnson Innovation, JLABS is hosting a microbiome-focused panel discussion with microbiome leaders from across big pharma, including one of the first movers in this emerging field, the Janssen Human Microbiome Institute, part of Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Hear from Pfizer, Merck, UCB, and Janssen at this unique meeting of the minds. The representatives will discuss:

  • The differences and similarities between the various research facilities cropping up in Cambridge.
  • What makes the microbiome exciting to pharma?
  • What is attractive to big pharma when it comes to the microbiome?
  • What's the best route forward for your company?

John Delyani | Executive Director, Business Development and Licensing, Merck read bio»
Dirk Gevers | Global Head, Janssen Human Microbiome Institute read bio»
Roger Palframan | Head Innovation Super Networks, UCB read bio»
Nilufer Seth | Senior Principal Scientist, Pfizer read bio»
Nikola Trbovic | Director, R&D Technology Strategy, Pfizer read bio»
[moderator] Bernat Olle | CEO, Vedanta Biosciences read bio»

2:00 PM | Registration Opens, Networking
2:30 PM | Investor Panel Discussion
3:30 PM | Q&A
4:00 PM | Networking Reception
4:30 PM | Program Close

$25 | General Public
$15 | Student/Academic
$35 | At the door

JLABS @ LabCentral
700 Main Street
Cambridge, MA 02139

Panelists' Biographies:

John Delyani, Ph.D. | Executive Director, Business Development and Licensing, Merck, Boston Innovation Hub
Dr. Delyani has approximately 20 years of experience in the pharmaceutical and biotechnology industry and has successfully completed over 30 transactions. He currently serves in the business development group at the Merck Boston Innovation Hub where he supports acquisition of external innovation across Merck's strategic interests, concentrating in cardio-metabolic and neurological diseases. Prior to Merck, John spent 8 years at the Novartis Institutes of BioMedical Research (NIBR) as Head of Search and Evaluation for NIBR's business development group where he led a team responsible for identifying and evaluating innovative partnering opportunities across all disease and technology platform areas and led selected transactions. Prior to joining NIBR, John was Senior Director of Business Development at Kalypsys, a biotechnology company focusing on metabolic, inflammation, and oncology small molecule therapeutics. John began his career at Searle/Pharmacia where he held positions of increasing levels of responsibility in R&D and business development, including Associate Director, Cardiovascular Research and Director of Technology Acquisitions. He holds a Ph.D. in cardiovascular physiology from the State University of New York at Buffalo and a MBA from Maryville University in St. Louis.
Connect with John:   Connect on LinkedIn

Dirk Gevers, Ph.D. | Global Head, Janssen Human Microbiome Institute, Janssen Research & Development
Dirk Gevers, Ph.D., is Global Head of the Janssen Human Microbiome Institute (JHMI), a group focused on accelerating the translation of microbiome research into breakthrough solutions that promote health. Dirk joined from his most recent role as Senior Group Leader of Microbial Systems and Communities at the Broad Institute of MIT and Harvard. In this position, Dirk served as a scientific liaison between different organizational components, including the Broad Institute's data generation platforms and both clinical and analytical collaborators on a number of microbiome-related projects. Dirk's research efforts at the Broad Institute included the characterization of the microbial imbalance associated with diseases such as Crohn's disease, type 1 diabetes and colorectal cancer. He was also involved with the National Institutes of Health (NIH) Human Microbiome Project (HMP), holding a leading role in the Data Analysis Working Group, consisting of over 50 investigators focused on human microbiome research. Dirk received his Ph.D. in biochemistry from Ghent University (UGent), Belgium, and completed postdoctoral training at UGent and Massachusetts Institute of Technology (MIT) in bioinformatics, comparative and evolutionary genome analysis and microbial ecology.
Connect with Dirk:   Connect on LinkedIn

Roger Palframan, Ph.D. | Head Innovation Super Networks, UCB
Roger Palframan is Head of Innovation Super Networks at UCB. In 2015 Roger established the UCB office in Cambridge MA, to build R&D collaborations with world leading research institutes and biotechnology companies. Roger gained his BSc in pharmacology at King's College London and his PhD in immunology at the National Heart and Lung Institute at Imperial College London. Roger was a Wellcome Trust Postdoctoral Research Fellow at Harvard Medical School where he investigated the molecular mechanisms of leukocyte trafficking. At UCB and previously at Celltech, Roger has held leadership roles across preclinical discovery research. Roger has successfully led clinical development programmes from pre-IND stage to proof-of-concept.
Connect with Roger:   Connect on LinkedIn

Nilufer Seth, Ph.D. | Senior Principal Scientist, Pfizer Global Research and Development
Nilufer Seth is currently in the Emerging Science Group in the Inflammation and Immunology Research Unit at Pfizer. She received her Ph.D. from Medical College of Augusta in Molecular Biology and Biochemistry. Nilufer did her post-doctoral training at the Dana-Farber Cancer Institute where her research focused on the design and development of novel approaches to ex vivo identify and analyze antigen-specific CD4 T cells subsets in human diseases and mouse models of autoimmunity. She studied antigen specific T cells from HIV and HCV infected individuals as well as in the NOD mouse model of Type 1 Diabetes. She joined the Department of Inflammation and Immunology at Wyeth where she led and worked on small and large molecule therapeutic programs targeting immune cells and inflammatory cytokines. Currently at Pfizer her focus is on developing medicines that will reshape the treatment of inflammatory and autoimmune diseases by harnessing strategies and pathways used by the human gut microbiota to maintain barrier and immune homeostasis.
Connect with Nilufer:   Connect on LinkedIn

Nikola Trbovic, Ph.D. | Director, R&D Technology Strategy, Pfizer
In his role as Director of R&D Technology Strategy, Nikola shapes and guides the deployment of Pfizer's investments in early-stage R&D platform technologies. In this capacity, he collaborates with colleagues across Pfizer to ensure Pfizer's ability to capitalize on breakthrough science to develop medicines that change peoples' lives. Prior to his current role, Nikola held responsibilities for early clinical portfolio management and R&D strategy. Nikola joined Pfizer from McKinsey Co., where he served as an Associate Principal and senior member of the Pharmaceuticals Practice, leading engagements with top pharmaceutical, biotech, and healthcare companies on a range of strategy, corporate finance and commercial topics across geographies and therapeutic areas. Nikola holds a Ph.D. in Biochemistry and Molecular Biophysics from Columbia University.
Connect with Nikola:   Connect on LinkedIn

[moderator] Bernat Olle, Ph.D. | Co-founder, Chief Executive Officer, Member of the BOD, Vedanta Biosciences
Dr. Olle is a co-founder and Chief Executive Officer of Vedanta Biosciences. He has been a member of the founding teams of four companies of the PureTech portfolio and serves as a member of the Board of Directors of Vedanta Biosciences and Follica Biosciences. In 2013 Dr. Olle was named "Innovator of the Year" in MIT Technology Review Spain's "Innovators under 35" awards, and in 2015 he was awarded the Princess of Girona business award by the King of Spain. He completed his doctoral work at the Chemical Engineering Department at MIT, where he developed a novel method for large scale bacterial culture. During his graduate work, Dr. Olle was awarded the "la Caixa" fellowship. Dr. Olle received his B.Eng. In Chemical Engineering from Universitat Rovira i Virgili, Spain, his M.S. and PhD in Chemical Engineering Practice from MIT, and his MBA from the MIT Sloan School of Management. He has published his work in journals including Nature and Nature Biotechnology.
Connect with Bernat:   Connect on LinkedIn

Johnson & Johnson Innovation, JLABS

About Johnson & Johnson Innovation, JLABS Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and healthtech sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to ten global locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto, Beerse (Belgium), New York City, and with Shanghai opening in 2019. For more information please visit www.jlabs.jnjinnovation.com or follow @JLABS.

Event contact

Related content